Minocycline Falls Short in Slowing Dry AMD Progression in Recent Study

The National Eye Institute, a division of the US National Institutes of Health, has disclosed that a second stage clinical study evaluating minocycline for the management of dry age-related macular degeneration did not meet its objectives of slowing atrophy. 

This oral medication failed to slow the loss of vision or the expansion of geographic atrophy among trial candidates. 

Dry age-related macular degeneration is a progressive eye condition affecting the macula, leading to central vision impairment due to the deterioration of light-sensitive cells in the retina. 

The study aimed to assess whether minocycline could inhibit microglial activity and mitigate the progression of geographic atrophy and associated vision impairment in individuals with dry AMD. 

However, the results demonstrated no significant disparity in the rate of atrophy expansion or the advancement of vision loss among those administered with minocycline.